Gong, Jiafen http://orcid.org/0000-0001-7760-1291
He, Gengming http://orcid.org/0000-0002-0971-8807
Wang, Cheng
Bartlett, Claire
Panjwani, Naim http://orcid.org/0000-0001-7551-0759
Mastromatteo, Scott http://orcid.org/0000-0002-3551-2247
Lin, Fan
Keenan, Katherine
Avolio, Julie
Halevy, Anat
Shaw, Michelle
Esmaeili, Mohsen
Côté-Maurais, Guillaume
Adam, Damien
Bégin, Stéphanie
Bjornson, Candice
Chilvers, Mark
Reisman, Joe
Price, April
Parkins, Michael
van Wylick, Richard http://orcid.org/0000-0003-1378-3799
Berthiaume, Yves
Bilodeau, Lara
Mateos-Corral, Dimas
Hughes, Daniel
Smith, Mary J.
Morrison, Nancy
Brusky, Janna
Tullis, Elizabeth
Stephenson, Anne L.
Quon, Bradley S.
Wilcox, Pearce
Leung, Winnie M. http://orcid.org/0000-0002-3003-8099
Solomon, Melinda
Sun, Lei http://orcid.org/0000-0002-5640-937X
Brochiero, Emmanuelle
Moraes, Theo J.
Gonska, Tanja
Ratjen, Felix
Rommens, Johanna M. http://orcid.org/0000-0001-8732-825X
Strug, Lisa J. http://orcid.org/0000-0003-0503-9740
Funding for this research was provided by:
Cystic Fibrosis Foundation (STRUG17PO)
Gouvernement du Canada | Canadian Institutes of Health Research (FRN 167282)
Cystic Fibrosis Canada (2626, CFIT program)
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (250053-2013, RGPIN-2015-03742)
Cystic Fibrosis Foundation Therapeutics (MORAES1610)
Article History
Received: 30 December 2021
Accepted: 4 March 2022
First Online: 8 April 2022
Competing interests
: L.B. participated in a Vertex Virtual Advisory Board and she is a member of the CF Annual Faculty, sponsored by Vertex Pharmaceuticals. D.M-C. received an honorarium for teaching module development for Vertex Pharmaceuticals. N. M. is doing contract research trials for Vertex Pharmaceuticals and Abbvie. A.L.S. has received speaking fees for educational programs sponsored by Vertex Pharmaceuticals. B.S.Q. has received speaker fees from Vertex Pharmaceuticals and has served as site PI for several Vertex-sponsored clinical trials. W.M.L. is a study investigator for Vertex Pharmaceuticals. E.T., T.G., and F.R. act as a consultant for Vertex Pharmaceuticals. M.S. participated in Vertex clinical trials and received payment for education modules. J.G., G.H., C.W., C. Bartlett, N.P., S.M., F.L., K.K., J.A., A.H., M.S., M.E., G.C-M., D.A., S.B., C.Bjornson, M.C., J.R., A.P., M.P., R.v.W., Y.B., D.H., M.J.S., J.B., P.W., L.S., E.B., T.M., J.M.R, and L.J.S. have no conflicts of interest.